In vitro activity of WIN 49375 compared with those of other antibiotics in isolates from cancer patients | Zendy

María Inmaculada GarcíaGarcía | Zendy; Gerald P. Bodey | Zendy; Victor Fainstein | Zendy; D H Ho | Zendy; Barbara LeBlanc | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

In vitro activity of WIN 49375 compared with those of other antibiotics in isolates from cancer patients

Author(s) -

María Inmaculada GarcíaGarcía,

Gerald P. Bodey,

Victor Fainstein,

D H Ho,

Barbara LeBlanc

Publication year - 1984

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.26.3.421

Subject(s) - serratia marcescens , enterobacter cloacae , microbiology and biotechnology , klebsiella pneumoniae , pseudomonas aeruginosa , in vitro , antibiotics , enterobacteriaceae , biology , enterobacter , escherichia coli , quinolone , bacteria , biochemistry , genetics , gene

The activity of WIN 49375 [6-fluoro-1, 4-dihydro-1-(methylamino)-7-(4-methyl-1-piperazinyl)-4-oxo-3- quinolinecarboxylic acid], a new synthetic quinolone, was tested in vitro against 587 clinical isolates. The MICs for 90% of isolates of Escherichia coli, Klebsiella pneumoniae, and Enterobacter cloacae were 0.20, 1.56, and 0.39 microgram/ml, respectively. The MICs for 90% of isolates of Pseudomonas aeruginosa and Serratia marcescens were both 3.12 micrograms/ml. WIN 49375 was minimally active against gram-positive cocci. Its in vitro activity suggests that it may be useful for the treatment of gram-negative bacillary infections.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research